Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.

Next Previous
Trial Profile

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 30 Jan 2020 Results (data cut off: December 31, 2016) assessing long-term efficacy and safety data from the trial after a median follow-up of 78.3 months published in the Cancer
  • 04 Dec 2018 Results after 5.7 years of follow up (n=22, data cut off: 30 Jun 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 26 Jul 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top